Score Breakdown
Trash.
Recursion is a speculative clinical-stage biotech burning $500M+ annually against ~$66M in lumpy milestone revenue, with a $2.2B accumulated deficit and 31%+ annual dilution. While the AI-driven drug discovery platform is intellectually compelling and partnerships with Sanofi/Roche provide non-dilutive capital, the company has yet to prove that its platform translates into superior clinical outcomes. The lead asset REC-4881 faces first-in-disease regulatory uncertainty, and the company is at least 3-5 years from any meaningful product revenue. At $1.46B market cap with 50% short interest and a 24-month cash runway requiring further dilution, the risk/reward is deeply unfavorable. SBC alone exceeds total revenue, and every dollar of market cap is built on optionality rather than fundamentals. The stock is priced for a future that requires multiple low-probability events to occur sequentially.
Negative cash flow. Can't value it.
Some yellow flags.
Shares melting fast.
Neutral.
Tight but ok.
Heavy bearish bets.
Decent.
🐻 Why Bears Hate It
The bear thesis centers on RXRX being a 'high-cash-burn, premium-valued biotech with unproven clinical success.' Despite a pivot toward oncology, the company remains years away from meaningful revenue, with its lead asset REC-4881 facing 'first-in-disease' regulatory uncertainty and no clear evidence that the Recursion OS platform actually improves drug success rates or reduces timelines compared to traditional methods. With a trailing twelve-month net loss of over $559 million, the company is effectively spending $23 for every $1 of revenue earned (Source: Seeking Alpha, Sahm Capital).
🔍 What's In The SEC Filings
The company is a high-burn speculative play reliant on continuous equity issuance to fund a $2.2 billion accumulated deficit despite large cash reserves.
Aggressive share count expansion via acquisitions and ATM offerings.
“Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares) [jumped from] 402,771,972 [to] 529,303,984.”
The 31.4% YoY increase in share count is driven by the Exscientia and Valence acquisitions and ATM sales; a new $300M TD Cowen ATM agreement was established in Feb 2026 to further this trend.
Substantial long-term cash/equity obligation to Tempus AI.
“Recursion is making annual payments, ranging between $22.0 million and $42.0 million, up to $160.0 million in aggregate, to Tempus.”
This mandatory spend for data access acts as a 'hidden' debt-like obligation that must be settled in cash or further dilutive equity, regardless of R&D success.
Sharp 56% decline in quarterly revenue and reliance on cost-to-cost recognition.
“Total revenue [for 3 months ended Mar 31, 2026] 6,472 [vs] 14,745 [for Mar 31, 2025].”
Revenue is recognized based on 'costs incurred relative to total expected costs.' This allows for revenue acceleration if expenses rise, but the current drop suggests a lull in milestone achievements or partnership activity.
Persistent burn and massive accumulated deficit.
“As of March 31, 2026, the Company had an accumulated deficit of $2.2 billion.”
With a quarterly operating loss of $128.5M and cash of $654.5M, the current runway is approximately 15 months without further dilution or milestone payments.
The intrinsic value is highly sensitive to the 'cost-to-cost' revenue model and the probability of hitting 'constrained' milestones; investors should discount for near-certain future dilution via the $300M ATM.
Ongoing litigation with Industry Office SLC involves claims of 'fraudulent misrepresentation' and 'anticipatory repudiation' regarding laboratory space, which could result in un-provisioned cash outflows.